Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement
Allergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
